Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Marco Ruella, Anqi Dai et al.|Nature Medicine|2022Cited by 308
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, James N. Gerson et al.|Nature Medicine|2024Cited by 254
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Gianluca Gaïdano, Lodovico Terzi-di-Bergamo et al.|Blood|2015Cited by 215
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against CancerYong Gu Lee, Marco Ruella, Puneeth Guruprasad et al.|Cancer Discovery|2022Cited by 98
Genetic and phenotypic attributes of splenic marginal zone lymphomaFerdinando Bonfiglio, Estella Matutes, Alessio Bruscaggin et al.|Blood|2021Cited by 96